View More View Less
  • 1 Marosvásárhelyi Orvosi és Gyógyszerészeti Egyetem (Internal Medicine IV Gh., UMF Tg. Mureș), Marosvásárhely, Románia (Marinescu str. 1., 540400 Târgu Mureş, Romania)
  • 2 Marosvásárhelyi Orvosi és Gyógyszerészeti Egyetem (UMF Tg. Mureș), Marosvásárhely, Románia
  • 3 Marosvásárhelyi Orvosi és Gyógyszerészeti Egyetem (UMF Tg. Mureș), Marosvásárhely, Románia
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Absztrakt:

A diabetes és szívelégtelenség társulása igen gyakori, ugyanakkor a két kórkép patofiziológiája és kórlefolyása is számos ponton találkozik. Napjainkban a rendelkezésre álló antidiabetikus gyógyszerek spektruma rendkívül széles, a klasszikus szerektől (inzulin, biguanidok, szulfanilureák) a legmodernebbekig (gliptinek, gliflozinok) terjed. Ezeknek a gyógyszereknek a cardiovascularis hatásai sokrétűek, ismeretük fontos a mindennapi gyakorlatban, ugyanis előnyben részesül a szívelégtelenség szempontjából biztonságos szerek alkalmazása. Munkánk áttekintést nyújt az egyes gyógyszercsoportokról – a hatásmechanizmus, valamint a főbb képviselők bemutatása után ismertetjük a cardiovascularis rendszerre és ezen belül a szívelégtelenségre gyakorolt hatásokat, megemlítve a fontosabb klinikai vizsgálatok eredményeit is. Az adatok egyértelműen alátámasztják a metformin és a gliflozinok kedvező és a thiazolidindionok káros hatását szívelégtelenségben. A többi gyógyszercsoport alkalmazása megengedett szívelégtelenség esetén, de fontos a dekompenzáció jeleinek folyamatos monitorozása. Orv. Hetil., 2017, 158(5), 163–171.

  • 1

    Tamayo, T., Rosenbauer, J., Wild, S. H., et al.: Diabetes in Europe: an update. Diabetes Res. Clin. Pract., 2014, 103(2), 206–217.

  • 2

    Kannel, W. B., Hjortland, M., Castelli, W. P.: Role of diabetes in congestive heart failure: the Framingham study. Am. J. Cardiol., 1974, 34(1), 29–34.

  • 3

    Dei Cas, A., Khan, S. S., Butler, J., et al.: Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail., 2015, 3(2), 136–145.

  • 4

    Cubbon, R. M., Adams, B., Rajwani, A., et al.: Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. Diab. Vasc. Dis. Res., 2013, 10(4), 330–336.

  • 5

    Dei Cas, A., Fonarow, G. C., Gheorghiade, M., et al.: Concomitant diabetes mellitus and heart failure. Curr. Probl. Cardiol., 2015, 40(1), 7–43.

  • 6

    Rydén, L., Grant, P. J., Anker, S. D., et al.: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J., 2013, 34(39), 3035–3087.

  • 7

    Low Wang, C. C., Reusch, J. E.: Diabetes and cardiovascular disease: Changing the focus from glycemic control to improving long-term survival. Am. J. Cardiol., 2012, 110(9 Suppl.), 58B–68B.

  • 8

    Kumar, R., Kerins, D. M., Walther, T.: Cardiovascular safety of anti-diabetic drugs. Eur. Heart J. Cardiovasc. Pharmacother., 2016, 2(1), 32–43.

  • 9

    Azimova, K., San Juan, Z., Mukherjee, D.: Cardiovascular safety profile of currently available diabetic drugs. Ochsner J., 2014, 14(4), 616–632.

  • 10

    Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., et al.: Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2015, 58(3), 429–442.

  • 11

    Turnbull, F. M., Abraira, C., Anderson, R. J., et al:. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia, 2009, 52(11), 2288–2298.

  • 12

    Muniyappa, R., Montagnani, M., Kon, K. K., et al.: Cardiovascular actions of insulin. Endocr. Rev., 2007, 28(5), 463–491.

  • 13

    Fitchett, D. H., Udell, J. A., Inzucchi, S. E.: Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur. J. Heart Fail., 2017, 19(1), 43–53. [Epub 2016 Sep 21]

  • 14

    UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352(9131), 837–853.

  • 15

    Gerstein, H. C., Bosch, J., Dagenais, G. R., et al., ORIGIN Trial Investigators: Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med., 2012, 367(4), 319–328.

  • 16

    Smooke, S., Horwich, T. B., Fonarow, G. C.: Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am. Heart J., 2005, 149(1), 168–174.

  • 17

    Winkler, G.: Metformin – new data of an “old”, but efficient, safe and reliable antidiabetics. [Metformin – újabb adatok egy megbízható és hatékony „régi” vércukorcsökkentő készítményről.] Orv. Hetil., 2016, 157(23), 882–891. [Hungarian]

  • 18

    El Messaoudi, S., Rongen, G. A., de Boer, R. A., et al.: The cardioprotective effects of metformin. Curr. Opin. Lipidol., 2011, 22(6), 445–453.

  • 19

    UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352(9131), 854–865.

  • 20

    Lamanna, C., Monami, M., Marchionni, N., et al.: Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes. Metab., 2011, 13(3), 221–228.

  • 21

    Eurich, D. T., Weir, D. L., Majumdar, S. R., et al.: Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ. Heart Fail., 2013, 6(3), 395–402.

  • 22

    Eurich, D. T., Majumdar, S. R., McAlister, F. A., et al.: Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care, 2005, 28(10), 2345–2351.

  • 23

    Masoudi, F. A., Inzucchi, S. E., Wang, Y., et al.: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation, 2005, 111(5), 583–590.

  • 24

    Shah, D. D., Fonarow, G. C., Horwich, T. B.: Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J. Card. Fail., 2010, 16(3), 200–206.

  • 25

    McAlister, F. A., Eurich D. T., Majumdar, S. R., et al.: The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur. J. Heart Fail., 2008, 10(7), 703–708.

  • 26

    Dreyer, C., Krey, G., Keller, H., et al.: Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell, 1992, 68(5), 879–887.

  • 27

    Nissen, S. E., Wolski, K.: Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med., 2010, 170(14), 1191–1201.

  • 28

    Timár, J.: Pancreatic hormones and the drugs for diabetes mellitus. In: Gyires, K., Fürst, Zs., Ferdinandy, P. (eds): Pharmacology and clinical pharmacology. [A pancreashormonok és a diabetes mellitus gyógyszerei. In: Gyires, K., Fürst, Zs., Ferdinandy, P. (szerk.): Farmakológia és klinikai farmakológia.] Medicina Könyvkiadó, Budapest, 2016, 294–313. [Hungarian]

  • 29

    Duan, S. Z., Usher, M. G., Mortensen, R. M.: PPARs: the vasculature, inflammation and hypertension. Curr. Opin. Nephrol. Hypertens., 2009, 18(2), 128–133.

  • 30

    Jermendy, Gy. (ed.): Diagnosis of diabetes, treatment and management of adult diabetic patients: Guidelines of the Hungarian Association of Diabetes, 2014. [A diabetes mellitus kórismézése, a cukorbetegek kezelése és gondozása felnőttkorban: A Magyar Diabetes Társaság szakmai irányelve, 2014.] Diabetol. Hung., 2014, 22 (Suppl. 1), 2–84. [Hungarian]

  • 31

    Goltsman, I., Khoury, E. E., Winaver, J., et al.: Does thiazolidinedione therapy exacerbate fluid retention in congestive heart failure? Pharmacol. Ther., 2016, 168, 75–97.

  • 32

    Erdmann, E., Charbonnel, B., Wilcox, R. G., et al., PROactive Investigators: Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care, 2007, 30(11), 2773–2778.

  • 33

    Lincoff, A. M., Wolski, K., Nicholls, S. J., et al.: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA, 2007, 298(10), 1180–1188.

  • 34

    Graham, D. J., Ouellet-Hellstrom, R., MaCurdy, T. E., et al.: Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA, 2010, 304(4), 411– 418.

  • 35

    Home, P. D., Pocock, S. J., Beck-Nielsen, H., et al., for the RECORD Study Team: Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet, 2009, 373(9681), 2125–2135.

  • 36

    Singh, S., Loke, Y. K., Furberg, C. D.: Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA, 2007, 298(10), 1189–1195.

  • 37

    Lago, R. M., Singh, P. P., Nesto R. W.: Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet, 2007, 370(9593), 1129–1136.

  • 38

    Joshi, P. H., Kalyani, R. R., Blumenthal, R. S., et al.: Cardiovascular effects of noninsulin, glucose-lowering agents: need for more outcomes data. Am. J. Cardiol., 2012, 110(9 Suppl.), 32B–42B.

  • 39

    Chiasson, J. L., Josse, R. G., Gomis, R., et al., for The STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA, 2003, 290(4), 486–494.

  • 40

    Hanefeld, M., Cagatay, M., Petrowitsch, T., et al.: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur. Heart J., 2004, 25(1), 10–16.

  • 41

    Van de Laar, F. A., Lucassen, P. L.: No evidence for a reduction of myocardial infarctions by acarbose. Eur. Heart J., 2004, 25 (13), 1179 –1180.

  • 42

    Winkler, G.: Sulfonylureas in today’s blood glucose lowering therapy. New data on advantages and potential barriers of an “old” antidiabetic group. [Szulfanilureák napjaink vércukorcsökkentő kezelésében. Újabb adatok egy régi gyógyszercsoport előnyeiről és korlátairól.] Orv. Hetil., 2015, 156(13), 511–515. [Hungarian]

  • 43

    Heller, S. R., ADVANCE Collaborative Group: A Summary of the ADVANCE Trial. Diabetes Care, 2009, 32(Suppl. 2), S357–S361.

  • 44

    Rydén, L., Shahim, B., Mellbin, L.: Clinical implications of cardiovascular outcome trials in type 2 diabetes: from DCCT to EMPA-REG. Clin. Ther., 2016, 38(6), 1279–1287.

  • 45

    Hemmingsen, B., Schroll, J. B., Wetterslev, J.: Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open, 2014, 2(3), E162–E175.

  • 46

    Zoungas, S., Patel, A., Chalmers, J., et al., for the ADVANCE Collaborative Group: Severe hypoglycemia and risks of vascular events and death. N. Engl. J. Med., 2010, 363(15), 1410–1418.

  • 47

    Rados, D. V., Pinto, L. C., Remonti, L. R., et al.: The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med., 2016, 13(4), e1001992.

  • 48

    Schramm, T. K., Gislason, G. H., Vaag, A., et al.: Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur. Heart J., 2011, 32(15), 1900–1908.

  • 49

    Simpson, S. H., Lee, J., Choi, S., et al.: Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol., 2015, 3(1), 43–51.

  • 50

    Giles, T. D., Elkayam, U., Bhattacharya, M., et al.: Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. Congest. Heart Fail., 2010, 16(3), 111–117.

  • 51

    Pantalone, K. M., Kattan, M. W., Yu, C., et al.: The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol., 2009, 46(2), 145–154.

  • 52

    Tzoulaki, I., Molokhia, M., Curcin, V., et al.: Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ, 2009, 339, b4731.

  • 53

    Derosa, G., Mugellini, A., Ciccarelli, L., et al.: Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: A one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin. Ther., 2003, 25(2), 472–484.

  • 54

    Holman, R. R., Haffner, S. M., McMurray, J. J., et al., The NAVIGATOR Study Group: Effect of nateglinide on the incidence of diabetes and cardiovascular events. N. Engl. J. Med., 2010, 362(16), 1463–1476.

  • 55

    Schramm, T. K., Gislason, G. H., Vaag, A., et al.: Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur. Heart J., 2011, 32(15), 1900–1908.

  • 56

    Cioffi, G., Faggiano, P., Lucci, D., et al.: Left ventricular dysfunction and outcome at two-year follow-up in patients with type 2 diabetes: The DYDA study. Diabetes Res. Clin. Pract., 2013, 101(2), 236–242.

  • 57

    Lindamood, C. A., Taylor, J. R.: Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists. Clin. Ther., 2015, 37(3), 483–493.

  • 58

    Pi-Sunyer, X., Astrup, A., Fujioka, K., et al.: A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med., 2015, 373(1), 11–22.

  • 59

    Jeremendy, Gy.: Cardiovascular safety of incretin-based antidiabetic treatment – results of completed clinical trials. [Az inkretintengelyen ható antidiabetikumokkal végzett cardiovascularis biztonságossági tanulmányok eddigi tapasztalatai.] Orv. Hetil., 2016, 157(16), 603–610. [Hungarian]

  • 60

    Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al., for the LEADER Steering Committee on behalf of the LEADER Trial Investigators: Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med., 2016, 375(4), 311–322.

  • 61

    Pfeffer, M. A., Claggett, B., Diaz, R., et al., for the ELIXA Investigators: Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med., 2015, 373(23), 2247–2257.

  • 62

    Marso, S. P., Bain, S., Consoli, A., et al., for the SUSTAIN-6 Investigators: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med., 2016, 375(19), 1834–1844.

  • 63

    Chen, X. W., He, Z. X., Zhou, Z. W., et al.: Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin. Exp. Pharmacol. Physiol., 2015, 42(10), 999–1024.

  • 64

    Scirica, B. M., Bhatt, D. L., Braunwald, E., et al., for the SAVOR-TIMI 53 Steering Committee and Investigators: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med., 2013, 369(14), 1317–1326.

  • 65

    White, W. B., Cannon, C. P., Heller, S. R., et al., for the EXAMINE Investigators: Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med., 2013, 369(14), 1327–1335.

  • 66

    McGuire, D. K., Van der Werf, F., Armstrong, P. W., et al., for the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group: Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus. Secondary analysis of a randomized clinical trial. JAMA Cardiol., 2016, 1(2), 126–135.

  • 67

    Jermendy, Gy.: Cardiovascular safety of DPP-4-inhibitors – results of clinical trials completed so far. [A DPP-4-gátlók cardiovascularis biztonságossága – a napjainkig lezárult nagy klinikai tanulmányok eredményei.] Cardiologia Hungarica, 2015, 45(3), 199–205. [Hungarian]

  • 68

    Tahara, A., Takasu, T., Yokono, M., et al.: Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J. Pharmacol. Sci., 2016, 130(3), 159–169.

  • 69

    Simonyi, G.: New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors. [Új lehetőség a 2-es típusú diabetes mellitus oralis vércukorcsökkentő terápiájában: a nátrium-glükóz kotranszporter-2-gátlók.] Orv. Hetil., 2012, 153(18), 695–701. [Hungarian]

  • 70

    Zinman, B., Wanner, C., Lachin, J. M., et al., for the EMPA-REG OUTCOME Investigators: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med., 2015, 373(22), 2117–2128.

  • 71

    Wu J. H., Foote, C., Blomster, J., et al.: Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol., 2016, 4(5), 411–419.

  • 72

    Monami, M., Dicembrini, I., Mannucci, E.: Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetol., 2016 Aug 4. [Epub ahead of print]. Erratum in: Acta Diabetol., 2016 October 11.

    • Crossref
    • Export Citation

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Nov 2020 5 0 0
Dec 2020 1 0 0
Jan 2021 5 0 0
Feb 2021 16 0 0
Mar 2021 5 0 0
Apr 2021 5 0 0
May 2021 0 0 0